Song Sisi, Chen Huizhu, Ning Gang, Guo Yingkun, Li Xuesheng
Department of Radiology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China.
Department of Radiology, Deyang People's Hospital, Deyang, Sichuan, China.
Front Oncol. 2023 Mar 17;13:1149139. doi: 10.3389/fonc.2023.1149139. eCollection 2023.
This study aims to assess the clinical influence of enlarged cardiophrenic lymph nodes (CPLN) on staging computed tomography (CT) among patients with advanced ovarian cancer.
This retrospective cohort study included 320 patients with advanced epithelial ovarian cancer who underwent staging CT from May 2008 to January 2019. The CPLN diameter was the average of two radiologists' measurements. Enlarged CPLN was defined as a short-axis diameter of ≥5 mm. Clinical and imaging findings, management decisions, and progression-free survival(PFS) were compared between patients with and without enlarged CPLN.
Enlarged CPLN was found in 129 (40.3%) patients, which was significantly associated with more pelvic peritoneal carcinomatosis (odds ratio [OR]: 6.61 with 95% confidence interval [CI]: 1.51-28.99), and involved the greater omentum (OR: 6.41, 95% CI: 3.05-13.46), spleen capsule nodules (OR: 2.83, 95% CI: 1.58-5.06), and liver capsule nodules (OR: 2.55, 95% CI: 1.57-4.17). The optimal cytoreduction rates did not differ between patients with and without enlarged CPLN ( = 0.656). The presence of enlarged CPLN had a significant negative influence on PFS (median PFS, 23.5 vs. 80.6 months, respectively, CPLN ≥5 mm versus <5 mm; = 0.023) in patients with no RD after primary debulking surgery, but no adverse effect on PFS among patients with RD (median PFS, 28.0 vs. 24.4 months, respectively, CPLN ≥5 mm versus <5 mm; = 0.359). However, enlarged CPLN on staging CT did not affect PFS in patients treated with neoadjuvant chemotherapy, with (median PFS, 22.4 vs. 23.6 months, respectively, CPLN ≥5 mm versus <5 mm; = 0.360) or without RD (median PFS, 17.7 vs. 23.3 months, respectively, CPLN ≥5 mm versus <5 mm; = 0.400). The enlarged CPLN showed a decreased trend in 81.6% (n = 80) of the patients with enlarged CPLN. No significant difference was found in PFS ( = 0.562) between patients with decreased and increased in the size of CPLN.
Enlarged CPLN on staging CT is associated with more abdominal disease but is not reliable in predicting complete resection. Enlarged CPLN awareness is necessary for patients with a primary chance of complete resection of abdominal disease.
本研究旨在评估增大的心膈角淋巴结(CPLN)对晚期卵巢癌患者分期计算机断层扫描(CT)的临床影响。
这项回顾性队列研究纳入了2008年5月至2019年1月期间接受分期CT检查的320例晚期上皮性卵巢癌患者。CPLN直径为两名放射科医生测量值的平均值。增大的CPLN定义为短轴直径≥5mm。比较有和没有增大的CPLN的患者的临床和影像学表现、治疗决策以及无进展生存期(PFS)。
129例(40.3%)患者发现增大的CPLN,这与更多的盆腔腹膜癌转移显著相关(比值比[OR]:6.61,95%置信区间[CI]:1.51 - 28.99),并且累及大网膜(OR:6.41,95% CI:3.05 - 13.46)、脾包膜结节(OR:2.83,95% CI:1.58 - 5.06)和肝包膜结节(OR:2.55,95% CI:1.57 - 4.17)。有和没有增大的CPLN的患者的最佳肿瘤细胞减灭率无差异( = 0.656)。在初次肿瘤细胞减灭术后无残留病灶(RD)的患者中,增大的CPLN对PFS有显著负面影响(中位PFS分别为23.5个月和80.6个月,CPLN≥5mm与<5mm; = 0.023),但在有RD的患者中对PFS无不良影响(中位PFS分别为28.0个月和24.4个月,CPLN≥5mm与<5mm; = 0.359)。然而,分期CT上增大的CPLN对接受新辅助化疗的患者的PFS没有影响,有(中位PFS分别为22.4个月和23.6个月,CPLN≥5mm与<5mm; = 0.360)或无RD(中位PFS分别为17.7个月和23.3个月,CPLN≥5mm与<5mm; = 0.400)。在81.6%(n = 80)有增大的CPLN的患者中,增大的CPLN呈减小趋势。CPLN大小减小和增大的患者之间的PFS无显著差异( = 0.